II期临床研究-话题@MedSci

#II期临床研究#

109篇内容 | 2950人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1650032, encodeId=81e61650032a2, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, objectType=article, longId=216915, objectId=e8b0216915a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8b0216915a0, replyNumber=0, likeNumber=127, createdTime=2022-05-28, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8b0216915a0, moduleTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8b0216915a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650039, encodeId=fbca165003923, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=安可达III期临床研究设计及数据解读, objectType=article, longId=220755, objectId=9535220e55a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9535220e55a8, replyNumber=0, likeNumber=89, createdTime=2022-07-19, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9535220e55a8, moduleTitle=安可达III期临床研究设计及数据解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9535220e55a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650034, encodeId=a5701650034ab, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, objectType=article, longId=217312, objectId=e46321e31264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46321e31264, replyNumber=0, likeNumber=88, createdTime=2022-03-04, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46321e31264, moduleTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46321e31264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650026, encodeId=5b15165002655, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究, objectType=article, longId=212072, objectId=e36e2120e2eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e36e2120e2eb, replyNumber=0, likeNumber=61, createdTime=2022-01-31, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e36e2120e2eb, moduleTitle=Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e36e2120e2eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650038, encodeId=d66d16500386a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=79, createdTime=2022-02-23, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650023, encodeId=26af16500237b, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, objectType=article, longId=211275, objectId=f24b2112e55c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24b2112e55c, replyNumber=0, likeNumber=61, createdTime=2021-12-20, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24b2112e55c, moduleTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24b2112e55c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650022, encodeId=ed6c16500220e, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点, objectType=article, longId=210493, objectId=d849210493a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d849210493a6, replyNumber=0, likeNumber=89, createdTime=2022-01-16, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d849210493a6, moduleTitle=特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d849210493a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650035, encodeId=b69416500357d, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, objectType=article, longId=217525, objectId=c79c21e52563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c79c21e52563, replyNumber=0, likeNumber=60, createdTime=2021-11-26, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c79c21e52563, moduleTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c79c21e52563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650041, encodeId=0ff11650041d4, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, objectType=article, longId=221179, objectId=74cf2211e969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cf2211e969, replyNumber=0, likeNumber=75, createdTime=2022-10-29, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cf2211e969, moduleTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cf2211e969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650044, encodeId=96ae1650044ca, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人, objectType=article, longId=221687, objectId=bc7922168e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7922168e72, replyNumber=0, likeNumber=69, createdTime=2022-01-02, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7922168e72, moduleTitle=NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7922168e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650031, encodeId=77d81650031cd, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, objectType=article, longId=216786, objectId=af4a216e8623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4a216e8623, replyNumber=0, likeNumber=99, createdTime=2021-12-20, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4a216e8623, moduleTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4a216e8623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650015, encodeId=a52d16500150a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究, objectType=article, longId=204977, objectId=9fff2049e7bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fff2049e7bf, replyNumber=0, likeNumber=71, createdTime=2021-06-15, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fff2049e7bf, moduleTitle=新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fff2049e7bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650030, encodeId=b7bf1650030d0, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, objectType=article, longId=213384, objectId=18202133844d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18202133844d, replyNumber=0, likeNumber=62, createdTime=2021-09-09, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18202133844d, moduleTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18202133844d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650016, encodeId=87cc165001693, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=LX9211治疗神经性疼痛，即将开展II期临床研究, objectType=article, longId=205264, objectId=56012052643d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56012052643d, replyNumber=0, likeNumber=95, createdTime=2021-02-12, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56012052643d, moduleTitle=LX9211治疗神经性疼痛，即将开展II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56012052643d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650027, encodeId=6759165002e9f, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功, objectType=article, longId=212433, objectId=8b68212433dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b68212433dd, replyNumber=0, likeNumber=62, createdTime=2022-05-12, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b68212433dd, moduleTitle=NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b68212433dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650012, encodeId=ed94165001286, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持, objectType=article, longId=203842, objectId=f57420384247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f57420384247, replyNumber=0, likeNumber=64, createdTime=2021-07-20, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f57420384247, moduleTitle=“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f57420384247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650010, encodeId=3d6e1650010af, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, objectType=article, longId=202599, objectId=ad7320259999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7320259999, replyNumber=0, likeNumber=113, createdTime=2021-09-28, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7320259999, moduleTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad7320259999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650017, encodeId=d89e165001eaa, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功, objectType=article, longId=205725, objectId=edf1205e25a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf1205e25a9, replyNumber=0, likeNumber=112, createdTime=2021-11-07, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf1205e25a9, moduleTitle=NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf1205e25a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650024, encodeId=5eb41650024dc, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, objectType=article, longId=210709, objectId=659b210e098a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=659b210e098a, replyNumber=0, likeNumber=58, createdTime=2021-06-28, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=659b210e098a, moduleTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=659b210e098a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650029, encodeId=696d165002943, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, objectType=article, longId=213343, objectId=818f213343eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=818f213343eb, replyNumber=0, likeNumber=88, createdTime=2021-10-10, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=818f213343eb, moduleTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=818f213343eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床研究

2020-05-29

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18

2022-05-28

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

安可达III期临床研究设计及数据解读

2022-07-19

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究

2022-03-04

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究

2022-01-31

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2022-02-23

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功

2021-12-20

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点

2022-01-16

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索

2021-11-26

heli0118 (审核中...)

前往app查看评论内容

#II期临床研究#

Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究

2022-10-29

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人

2022-01-02

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究

2021-12-20

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究

2021-06-15

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新

2021-09-09

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

LX9211治疗神经性疼痛，即将开展II期临床研究

2021-02-12

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功

2022-05-12

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持

2021-07-20

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

拜耳Finerenone FIDELIO-DKD III期临床研究结果公布

2021-09-28

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功

2021-11-07

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果

2021-06-28

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C

2021-10-10

科室
- - 订阅+
  - 更多科室
工具
服务